Study: Anti-NGF drug could be effective treatment for OA patients

04/16/2013 | InternalMedicineNews.com (free registration)

Treatment of osteoarthritis of the hip with tanezumab, an anti-nerve growth factor, was found to significantly improve pain and physical function after 16 weeks, according to results from a Phase III study of 621 patients with painful hip OA. According to the study, tanezumab could be useful in treating OA patients who can't tolerate or don't respond to nonopioid treatments.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations